Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Berthony Deslouches, Jonathan D. Steckbeck, Jodi K. Craigo, Yohei Doi, Jane L. Burns, Ronald C. Montelaro

研究成果: Article

49 引用 (Scopus)

抄録

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

元の言語English
ページ(範囲)1329-1333
ページ数5
ジャーナルAntimicrobial agents and chemotherapy
59
発行部数2
DOI
出版物ステータスPublished - 01-02-2015

Fingerprint

Antimicrobial Cationic Peptides
Multiple Drug Resistance
Anti-Bacterial Agents
Colistin
Aptitude
Bacteria
Peptides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

Deslouches, Berthony ; Steckbeck, Jonathan D. ; Craigo, Jodi K. ; Doi, Yohei ; Burns, Jane L. ; Montelaro, Ronald C. / Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. :: Antimicrobial agents and chemotherapy. 2015 ; 巻 59, 番号 2. pp. 1329-1333.
@article{5d7f5b873523434389feee0e048e5ee8,
title = "Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens",
abstract = "Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.",
author = "Berthony Deslouches and Steckbeck, {Jonathan D.} and Craigo, {Jodi K.} and Yohei Doi and Burns, {Jane L.} and Montelaro, {Ronald C.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1128/AAC.03937-14",
language = "English",
volume = "59",
pages = "1329--1333",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. / Deslouches, Berthony; Steckbeck, Jonathan D.; Craigo, Jodi K.; Doi, Yohei; Burns, Jane L.; Montelaro, Ronald C.

:: Antimicrobial agents and chemotherapy, 巻 59, 番号 2, 01.02.2015, p. 1329-1333.

研究成果: Article

TY - JOUR

T1 - Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

AU - Deslouches, Berthony

AU - Steckbeck, Jonathan D.

AU - Craigo, Jodi K.

AU - Doi, Yohei

AU - Burns, Jane L.

AU - Montelaro, Ronald C.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

AB - Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84921894902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921894902&partnerID=8YFLogxK

U2 - 10.1128/AAC.03937-14

DO - 10.1128/AAC.03937-14

M3 - Article

C2 - 25421473

AN - SCOPUS:84921894902

VL - 59

SP - 1329

EP - 1333

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -